Skip to content

Validation study of food containing BARLEYmax on reducing body fat: Randomized double blind placebo control studies

Validation study of food containing BARLEYmax on reducing body fat: Randomized double blind placebo control studies - Validation study for reducing body fat by BARLEYmax

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028706
Enrollment
50
Registered
2017-08-17
Start date
2017-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Granola containing BARLEYmax, 1 food per day for 12 weeks Granola not containing BARLEYmax, 1 food per day for 12 weeks

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Males and females aged greater than 30 and less than 60 years old 2.Subjects who usually have 3 balanced meals a day except persons who eat fermented soybeans or granola everyday 3.Subjects with BMI greater than 23 and less than 30 kg/m^2 except persons under treatment of obesity 4.Subjects who usually drink alcohol once or twice a week at most 5.Subjets giving written informed consent

Exclusion criteria

Exclusion criteria: 1.Subjects who takes oral medication affecting obesity, hyperlipidemia and lipid metabolism 2.Subjects who suffer a severe illness in liver, cardiovascular, respiratory, endocrine, metabolism and allergy 3.Subjects who are not able to stop to take in food or supplement affecting obesity, hyperlipidemia and lipid metabolism 4.Subjects who have under treatment or a history of drug addiction and/or alcoholism 5.Subjects who have a metal component in the abdomen 6.Subjects who have a cardiac pacemaker 7.Subjects who have food allergy 8.Subjects who were diagnosed as familial hyperlipidemia 9.Pregnant and lactating female, or who wish to get pregnant during the study period 10. Subjects who is already participating or participated within 1 month in other clinical trials, subjects planning to participate during this examination period 11.Subjects who are ineligible due to physician's judgment

Design outcomes

Primary

MeasureTime frame
Abdominal visceral fat area, abdominal subcutaneous fat area, and abdominal total fat area, at 12weeks after intake

Secondary

MeasureTime frame
Body weight(BMI), abdominal circumherence, fasting blood sugar level and serum lipids(total cholesterol, LDL-cholesterol, Triglycerides), at 6 and 12weeks after intake Measurement of intestinal flora and adiponectin(polymer), at 12weeks Defecation frequency and stool output

Countries

Japan

Contacts

Public ContactEiji Yoshikawa

KSO Corporation Sales department

yoshikawa@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026